Stereotaxis, Inc. (NYSEAMERICAN:STXS - Free Report) - Stock analysts at Roth Capital cut their FY2024 earnings per share estimates for Stereotaxis in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of ($0.24) for the year, down from their previous estimate of ($0.22). The consensus estimate for Stereotaxis' current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Stereotaxis' Q4 2024 earnings at ($0.04) EPS, Q1 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.17) EPS.
Stereotaxis Stock Performance
STXS traded down $0.06 on Friday, reaching $2.03. 248,063 shares of the stock were exchanged, compared to its average volume of 295,153. Stereotaxis has a fifty-two week low of $1.47 and a fifty-two week high of $3.29. The stock has a market cap of $171.86 million, a P/E ratio of -7.45 and a beta of 1.55.
Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) last issued its earnings results on Monday, November 11th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.03). Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 153.10%. The firm had revenue of $9.20 million for the quarter, compared to the consensus estimate of $6.80 million.
Hedge Funds Weigh In On Stereotaxis
Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Stereotaxis during the first quarter worth $58,000. Vanguard Group Inc. increased its stake in Stereotaxis by 7.7% during the first quarter. Vanguard Group Inc. now owns 2,613,966 shares of the company's stock worth $6,822,000 after acquiring an additional 187,437 shares during the last quarter. Virtu Financial LLC increased its stake in Stereotaxis by 56.0% during the first quarter. Virtu Financial LLC now owns 32,690 shares of the company's stock worth $85,000 after acquiring an additional 11,739 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Stereotaxis by 247.5% during the second quarter. Bank of New York Mellon Corp now owns 189,592 shares of the company's stock worth $345,000 after buying an additional 135,041 shares during the period. Finally, Forum Financial Management LP purchased a new position in shares of Stereotaxis during the second quarter worth $48,000. Institutional investors and hedge funds own 45.35% of the company's stock.
About Stereotaxis
(
Get Free Report)
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
Read More
Before you consider Stereotaxis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stereotaxis wasn't on the list.
While Stereotaxis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
